These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3958917)

  • 1. Mixing-tank model for predicting dissolution rate control or oral absorption.
    Dressman JB; Fleisher D
    J Pharm Sci; 1986 Feb; 75(2):109-16. PubMed ID: 3958917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs.
    Macheras P; Iliadis A; Melagraki G
    Eur J Pharm Sci; 2018 May; 117():98-106. PubMed ID: 29425862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.
    Takano R; Sugano K; Higashida A; Hayashi Y; Machida M; Aso Y; Yamashita S
    Pharm Res; 2006 Jun; 23(6):1144-56. PubMed ID: 16715363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation.
    Takano R; Furumoto K; Shiraki K; Takata N; Hayashi Y; Aso Y; Yamashita S
    Pharm Res; 2008 Oct; 25(10):2334-44. PubMed ID: 18560998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissolution Kinetics of a BCS Class II Active Pharmaceutical Ingredient: Diffusion-Based Model Validation and Prediction.
    Gao Y; Glennon B; He Y; Donnellan P
    ACS Omega; 2021 Mar; 6(12):8056-8067. PubMed ID: 33817465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets.
    Maeda T; Takenaka H; Yamahira Y; Noguchi T
    J Pharm Sci; 1979 Oct; 68(10):1286-9. PubMed ID: 512862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles.
    Wong SM; Kellaway IW; Murdan S
    Int J Pharm; 2006 Jul; 317(1):61-8. PubMed ID: 16647232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated model for determining causes of poor oral drug absorption.
    Yu LX
    Pharm Res; 1999 Dec; 16(12):1883-7. PubMed ID: 10644078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance in the setting of drug particle size specifications to minimize variability in absorption.
    Johnson KC; Swindell AC
    Pharm Res; 1996 Dec; 13(12):1795-8. PubMed ID: 8987073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
    Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
    Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical model for dose-dependent drug absorption.
    Dressman JB; Fleisher D; Amidon GL
    J Pharm Sci; 1984 Sep; 73(9):1274-9. PubMed ID: 6548523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational oral absorption simulation of free base drugs.
    Sugano K
    Int J Pharm; 2010 Oct; 398(1-2):73-82. PubMed ID: 20655999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study.
    Fujioka Y; Kadono K; Fujie Y; Metsugi Y; Ogawara K; Higaki K; Kimura T
    J Control Release; 2007 Jun; 119(2):222-8. PubMed ID: 17442444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast-dissolving microparticles fail to show improved oral bioavailability.
    Wong SM; Kellaway IW; Murdan S
    J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of drugs: the digoxin dilemma.
    Greenblatt DJ; Smith TW; Koch-Weser J
    Clin Pharmacokinet; 1976; 1(1):36-51. PubMed ID: 797491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug.
    Fujioka Y; Metsugi Y; Ogawara K; Higaki K; Kimura T
    Int J Pharm; 2008 Mar; 352(1-2):36-43. PubMed ID: 18037251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of human pharmacokinetics--gastrointestinal absorption.
    Fagerholm U
    J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs.
    Kataoka M; Masaoka Y; Yamazaki Y; Sakane T; Sezaki H; Yamashita S
    Pharm Res; 2003 Oct; 20(10):1674-80. PubMed ID: 14620525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.